Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
Nevirapine associated rash has been well described in the Caucasian population. With increasing access to antiretroviral treatment--especially a fixed dose combination--by people living with HIV/AIDS in developing countries, there is a need to emphasize the lead in doses of nevirapine. We strongly recommend a warning label on the bottle advising patients on the lead-in period and the signs and symptoms of significant rash.
Daniel
Olusoji J
OJ
Centre for Special Studies Nigeria, Olabissi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria. sojidaniel@yahoo.com
Krain
Alysa B
AB
Ogun
Shamsideen A
SA
Odusoga
Okanlawon L
OL
Boyle
Brian A
BA
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004338:Drug Combinations; D005076:Exanthema / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D013577:Syndrome
D019380:Anti-HIV Agents; D004338:Drug Combinations; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine